Bedaquiline Fumarate

Increased Mortality; QT Prologation

  • An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,2.5%) in one placebo-controlled trial. Only use SIRTURO when an effective treatment regimen cannot otherwise be provided.
  • QT prolongation can occur with SIRTURO. Use with drugs that prolong the QT interval may cause additive QT prolongation.

Patient counseling

Medical guidelines

Patient Medication Guide

Package inserts

Bedaquiline fumarate

Keywords: Sirturo
Updated: September 2016